Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jenburkt PharmaceuticalsBOM:524731 +1.11%82 Gross Margin % is 80.59% as of Mar. 2026, which is 10% above its 10-year median of 73.07. GuruFocus rates BOM:524731 with a GF Score™ of 82/100 and a GF Value™ of ₹1,116.32 (Fairly Valued). The stock has 1 warning sign investors should review. Among 942 Drug Manufacturers companies, Jenburkt Pharmaceuticals ranks better than 92.89% on this metric.
BOM:524731's Gross Margin % is ranked better than 92.89% of 942
companies
in the Drug Manufacturers industry
Industry Median: 48.54
vs BOM:524731: 80.84
Jenburkt Pharmaceuticals had a gross margin of 80.59% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Jenburkt Pharmaceuticals had a gross margin of 80.59% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Jenburkt Pharmaceuticals Gross Margin % Related Terms
Jenburkt Pharmaceuticals Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:524731 vs ZTS, UTHR: Gross Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Jenburkt Pharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jenburkt Pharmaceuticals Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jenburkt Pharmaceuticals's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Jenburkt Pharmaceuticals's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Jenburkt Pharmaceuticals (BOM:524731) has a Gross Margin % of 80.59% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Jenburkt Pharmaceuticals and its competitors. This is 10% above median its historical median of 73.07. Over the past decade, Jenburkt Pharmaceuticals' Gross Margin % has ranged from 69.78 to 80.84. According to the industry distribution chart, Jenburkt Pharmaceuticals ranks #67 out of 942 companies in the Drug Manufacturers industry, placing it in the top 7.1%.
Is Jenburkt Pharmaceuticals' Gross Margin % too high?
Jenburkt Pharmaceuticals' current Gross Margin % of 80.59% is 10% above median its 10-year median of 73.07. Over the past 10 years, this metric has ranged from a low of 69.78 to a high of 80.84. The Drug Manufacturers industry median Gross Margin % is 48.54. Jenburkt Pharmaceuticals' value of 80.59% is 66% above this industry median. Based on the distribution chart, Jenburkt Pharmaceuticals ranks #67 out of 942 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Jenburkt Pharmaceuticals has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Jenburkt Pharmaceuticals' Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Jenburkt Pharmaceuticals ranks #67 out of 942 companies for Gross Margin %. This places Jenburkt Pharmaceuticals in the top 7% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 48.54. Jenburkt Pharmaceuticals' value of 80.59% is 66% above this benchmark. Historically, Jenburkt Pharmaceuticals' own Gross Margin % has ranged from 69.78 to 80.84 over the past decade. While the company's 10-year median is 73.07 vs. the industry median of 48.54, Jenburkt Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 942 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jenburkt Pharmaceuticals's current Gross Margin % of 80.59% is 66% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Jenburkt Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jenburkt Pharmaceuticals's current Gross Margin % is 80.59%, which is 10% above median its own 10-year median of 73.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jenburkt Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Jenburkt Pharmaceuticals (BOM:524731) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,116.32, compared to a current price of ₹1,101.45 — trading 1.3% below its estimated fair value. The current Gross Margin % is 80.59%, which is 10% above median its 10-year median of 73.07 and 66% above the Drug Manufacturers industry median of 48.54. Jenburkt Pharmaceuticals' overall GF Score™ is 82/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Jenburkt Pharmaceuticals (BOM:524731), the current Gross Margin % is 80.59% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jenburkt Pharmaceuticals (BOM:524731) Overvalued in 2026?
Based on GuruFocus' analysis, Jenburkt Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹1,101.45 is trading 1.3% below its estimated GF Value™ of ₹1,116.32.
GuruFocus considers Jenburkt Pharmaceuticals to be Fairly Valued.
Key valuation signals for BOM:524731:
Gross Margin %: 80.59% (10% above median its 10-year median of 73.07)
GF Value™: ₹1,116.32 vs. price of ₹1,101.45 (1.3% below fair value)
Industry Position: 66% above the Drug Manufacturers median (#67 of 942)
No single metric tells the full story. See the BOM:524731 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jenburkt Pharmaceuticals Ltd is engaged in the manufacturing, producing, developing, and marketing of pharmaceutical formulations. The company operates in one segment - pharmaceutical formulations. The company generates key revenue from the local market.
82GF Score
Get the complete analysis for BOM:524731
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524731 has been successfully added to your 
